Established in 2013, Mstone Healthcare Partners is an incubator of biotech, healthcare and AI companies. Mstone founds, staffs, develops, and grows portfolio companies by building upon novel technology as well as human and investment capital.
We believe that not all development is the same and whether in life sciences, healthcare or AI, our approach is to leverage technologies that address a demonstrated need, are well-positioned for growth and commercialization, and promise attractive market positions.
Our portfolio companies all seek to affect transformational change by partnering, licensing, and co-developing our businesses and assets in an interest-aligned manner. We also efficiently manage capital deployment as we reach corporate milestones and create substantive inflection points to reflect significant economic value.
Corporate Structure
Mstone Portfolio Companies
-
Rare pediatric drugs for the treatment of lysosomal storage disorders, including Batten Disease, Krabbe Disease, and Niemann-Pick Disease. Approved to launch pivotal trials
Founded
2016
-
Rare pediatric drugs for treatment of metabolic disorders such as non-ketonic hyperglycinemia, urea cycle disorders, with IND approved in 2022
Founded
2021
-
Drugs for the treatment of autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, among others, currently in pre-clinical stage
Founded
2020
-
Medical- and non-medical grade aesthetic products distributed globally with Korean R&D and manufacturing
Founded
2017
-
A platform developing smart AI technology to revolutionize healthcare delivery and management, focusing on the roll-out of an AI-powered B2B2C digital clinic app
Founded
2024
-
An innovative aesthetic clinic franchise powered by AI technologies and distribution channels to build & grow a global franchise
Founded
2024
-
Acquired April 2024
Rare pediatric drugs for the treatment of refractory epileptic disorders, including Dravet and Lennox-Gastaut Syndromes, in pivotal clinical trials
Founded
2016